Nuance Investments LLC Decreases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Nuance Investments LLC lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 149,413 shares of the medical equipment provider’s stock after selling 15,270 shares during the period. Nuance Investments LLC owned approximately 0.07% of Hologic worth $10,771,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in HOLX. FMR LLC lifted its position in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the period. Boston Partners boosted its stake in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Hologic during the 4th quarter valued at about $27,007,000. Finally, Teacher Retirement System of Texas increased its position in shares of Hologic by 82.9% during the 4th quarter. Teacher Retirement System of Texas now owns 649,883 shares of the medical equipment provider’s stock valued at $46,850,000 after purchasing an additional 294,538 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 1.8 %

HOLX stock opened at $60.80 on Wednesday. The firm’s fifty day simple moving average is $65.70 and its two-hundred day simple moving average is $73.66. The stock has a market capitalization of $13.64 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HOLX. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of “Hold” and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.